Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (a foreign private issuer) for the month of January 2017, with a report date of January 30, 2017. The filing serves to disclose a material corporate event regarding executive leadership changes.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel announcement and does not contain financial statements or performance metrics.
Material Changes
- Executive Appointment: Dr. Yaron Pereg was appointed as Chief Development Officer.
- Executive Resignation: Dr. Nadir Askenasy resigned as Chief Technology Officer, creating the vacancy filled by Dr. Pereg.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document is a standard disclosure of a change in key personnel.
Key Facts for Investor Verification
- Verify the background and qualifications of the new Chief Development Officer, Dr. Yaron Pereg.
- Confirm the effective date of Dr. Nadir Askenasy's resignation and the transition plan for the Chief Technology Officer role.
- Review the company's Form S-8 (Registration No. 333-214817) referenced in the filing for related equity incentive plan details.